Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

4 trials in Phase 3/4

Results Transparency

0 of 12 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

9(56.3%)

Phase 3

4(25.0%)

Phase 2

2(12.5%)

Early Phase 1

1(6.3%)

16Total

Phase 1(9)

Phase 3(4)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT07347080Early Phase 1Not Yet Recruiting

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

Role: collaborator

NCT06350812Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Role: lead

NCT06147544Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.

Role: lead

NCT04504396Phase 3Completed

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Role: lead

NCT04504370Phase 3Completed

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Role: lead

NCT05021666Phase 1Completed

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

Role: lead

NCT05326490Phase 3Unknown

Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

Role: lead

NCT05328843Phase 1Unknown

Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

Role: lead

NCT05102149Phase 3Unknown

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Role: lead

NCT03973515Phase 1Completed

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT03520972Phase 2Completed

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

Role: lead

NCT03604419Phase 2Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Role: lead

NCT03072407Phase 1Completed

MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

Role: lead

NCT03062774Phase 1Completed

Continuous Multiple Dose PB-119 Injection in Health Volunteers

Role: lead

NCT03059719Phase 1Completed

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT02084251Phase 1Completed

Clinical Trial for PB-119 in Healthy Subjects (Phase I)

Role: lead

All 16 trials loaded